RE: i_d_y_m = BIOEYEexcellent work inequities.
i recall Vera and her "controversial" report on onc - she was one of the few analysts that actually covered onc and if i remember correctly she was not nearly as bullish as wayne schnarr's $50 18 month target at cannacord. in fact, i think her target was $5 or something like that, well below the stock price at the time of her report (ie it was a sell rating).
many were up in arms, especially BIOEYE and the so called "credible" posters - yet Vera was ultimately proven right and "more credible" posters like BIOEYE & others (many of whom are still around and posting on onc) were, together with schnarr, left with egg on their face, much to their chagrin. even then, i don't think many ever gave her even grudging respect for being right.
the more i read current posts by these so called more "credible" posters, after having re-read many of their earlier "material", the more i am inclined to view them as fairly reliable contrary indicators, particularly BIOEYE (the one who represents herself with the quick and considerable access to BT & MC). the hype is almost never followed by real substance or follow through.
that has been the story for onc most of the 6 years of its existence.
it is time to bring accountability to management.
it is time for Brad Thompson to voluntarily step down as chairman of the board and for a new chair to eliminate the royalty agreement. in exchange, the "founders and Brad Thompson, should receive a commensurate number of oncy shares that will put management's interest directly and completely in alignment with the owners of the company.